Adenocarcinoma gastric+1
Not yet recruitingA Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)
A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)
- Disease:Adenocarcinoma gastricOesophageal adenocarcinoma
- Substances:CapecitabineFluorouracil+6
Germany- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:Astellas Pharma Global Development Inc.



